Trinity Biotech revenue up 16.4% to €19.7m

TRINITY Biotech, the Bray, Co Wicklow-based pharmaceutical company, has reported a 16.4% increase in first-quarter revenues to $24.7 million (€19.7m) for the three months to the end of March.

The Nasdaq and Irish Stock Exchange-quoted company, which develops and manufactures diagnostic products for the point-of-care and clinical laboratory markets, recorded a like-for-like increase in operating profits from $1.4m (€1.2m) to $2m (€1.6m) and a 23.5% growth in after-tax profits, over the same timeframe, from $1m (€800,000) to $1.2m (€957,000).

Rory Nealon, Trinity’s chief financial officer, said growth had been achieved in each of the company’s geographical markets. The company operates in Europe, North America, Asia and Africa.